Overview
- China’s drug regulator approved BoruiKang’s implanted brain–computer interface for hand grasp compensation in March, describing it as the first registered invasive BCI medical device globally.
- Shanghai Stock Exchange updated the company’s Sci‑Tech Board IPO status to “accepted,” starting formal public-review procedures that must clear further compliance checks before a listing can proceed.
- The approved device is a multi-part system that includes an implantable module, electrode kit, signal transceiver, a pneumatic glove and decoding and clinical management software for patients with spinal cord injury‑related paralysis.
- BoruiKang’s prospectus shows rising revenue from 2023 to 2025 but continuing net losses, with 2025 revenue about RMB 108 million and a reported net loss of RMB 230 million, highlighting uncertainty about near‑term commercial profitability.
- Founded in 2011, the company built a platform across noninvasive and minimally invasive BCIs, a technical base that could enable clinical rollout but will require scaled manufacturing, payer coverage and wider clinical adoption to affect patient access.